Cells Cor.At murine ESC derived cardiomyocytes and inactivated murine embryonic fibroblasts (MEF)
Species Mouse
Delivery  A study protocol will be sent to initiate the study. Results are sent as draft and final study report.
Timelines
Experiment time: 2 weeks per compound.
Draft report: within 4 weeks.
Service content Investigation of cardiac specific cytotoxic effects of test compounds on Cor.At cardiomyocytes compared to MEF.
Reporter TAQ GFP or CL

 

 order
 

Create PDF Recommend Print

Cor.At Tox - cardiac-specific cytotoxicity

Cor.At® cardiomyocytes provide a standardized, homogenous and reproducible cell system for the in vitro classification of a compound‘s cardio-cytotoxic potential. After incubation with test compounds, the Neutral Red Uptake test is used to determine effects which directly affect the viability and integrity of cardiac cellswhen compared to a non-specific reference cell type, e.g. mouse fibroblasts.

The assay has been validated in-house using > 40 drugs with known cardiac safety profile to predict cardiac specific cytotoxicity of test compounds. The validation study revealed specificity, sensitivity, and positive and negative predictive values of > 90% each. Reference compounds are run within each test to ensure reproducible results.

It is possible to combine the Cor.At Tox test with an assay for  troponin release in the cell culture supernatant.

Advantages Cor.At Tox®  service
  • Integrated cell culture model representing primary-like cardiac physiology.
  • Predictive, relevant and robust test system capable of medium to high throughput screening.
  • Various read-outs of cell viability and cytotoxicity possible.
  • Comparison with possible effects on cardiac electrophysiology and mitochondrial function within the same cell system.
  • Early and quick results on cardiac toxicity, time- and cost effective.
  • Either standardized or customized protocols available with respect to drug treatment period, concentrations, and read-out.